Teladoc Health Inc vs Tilray Brands Inc — how do they compare? Teladoc Health Inc trades at $5.64 (market cap $1.01B), while Tilray Brands Inc trades at $3.47 (market cap $530.54M). The key difference: Teladoc Health Inc is the larger of the two by market cap, and Teladoc Health Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and Tilray Brands Inc for 31 Days on average.
| TDOC | TLRY | |
|---|---|---|
Market Cap | $1.01B | $530.54M |
Volume | 4,668,477 | 9,099,075 |
Sector | Health | Health |
52-Week High | $9.72 | $21.00 |
52-Week Low | $4.47 | $3.57 |
Typical Hold Time | 39 Days | 31 Days |
Enterprise Value | $1.27B | $684.46M |
Signals from Pluang's Aura AI — not financial advice
Teladoc Health (TDOC) trades at $5.56, down 3.64% on the day, reflecting persistent bearish technical signals and negative earnings. The stock shows weak profitability with a net income margin of -7.13% and negative ROE, though valuation ratios like P/S of 0.4 and EV/EBITDA of 5.89 appear low. Recent news includes a CFO transition and ongoing investor investigations, adding to uncertainty.
The outlook remains challenging due to consecutive net losses and competitive pressures, but the consensus price target of $8.83 suggests potential upside if operational improvements materialize. Key risks include sustained unprofitability, high debt levels, and weak sentiment, requiring careful monitoring of cost management and revenue stabilization efforts.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →